| Project/Area Number |
18K05996
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 42020:Veterinary medical science-related
|
|---|
| Research Institution | University of Miyazaki |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | リキッドバイオプシー / 細胞外小胞 / エクソソーム / 細胞浸潤 / 腎障害 |
|---|
| Outline of Final Research Achievements |
The aim of this study is the search of biomarker for the liquid-biopsy to diagnose the cellular infiltration in the kidney injury. I examined whether immune cell marker proteins such as CD8, a marker of cytotoxic T cell, were released into the urinary extracellular vesicles (uEV) in the allogenic renal transplant model rat (Tp group) or not. As a result, CD8 in uEV could be detected in Tp group but not in control group. In addition, TSG101, a uEV marker, was increased in uEV of Tp group. TSG101 was expressed in the infiltration cells and TSG101 level in uEV was correlated with the cellular infiltration area in the kidney. In summary, the combination of CD8 and TSG101 in uEV may be potential non-invasive biomarkers for the liquid-biopsy to diagnose the cellular infiltration with cytotoxic T cells in the kidney.
|
| Academic Significance and Societal Importance of the Research Achievements |
AKIの罹患率は入院患者で多く、その死亡率は40％と非常に高い。また、日本におけるCKD患者は1000万人以上といわれており、腎疾患は国民の健康に重大な影響を与えている疾患である。獣医領域においても感染症を除いて、尿毒症はウシでのと畜禁止の原因の上位であり、小動物分野では腎疾患はイヌ・ネコの死亡原因の3位以内にランクインする。このように、医学領域と獣医領域の両方で、腎疾患は罹患率および死亡率を低下させるための研究が求められている。本研究は様々な腎臓病において共通してみられる細胞浸潤に着目し、リキッドバイオプシーという、非侵襲的なバイオマーカーを用いた診断方法の新規開発に寄与するものである。
|
